AVDL

Avadel Pharmaceuticals
AVDL

$16.72

2.64%

Market Cap: 1.61B

About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Employees: 154

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 11 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

67% more funds holding in top 10

Funds holding in top 10: 6 [Q4 2023] → 10 (+4) [Q1 2024]

61% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 23

49% more capital invested

Capital invested by funds: $792M [Q4 2023] → $1.18B (+$391M) [Q1 2024]

41% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 29

14.85% more ownership

Funds ownership: 62.47% [Q4 2023] → 77.32% (+14.85%) [Q1 2024]

13% more funds holding

Funds holding: 111 [Q4 2023] → 125 (+14) [Q1 2024]

46% less call options, than puts

Call options by funds: $24.3M | Put options by funds: $45.1M

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$21

26%

upside

Avg. target

$23

40%

upside

High target

$29

73%

upside

11 analyst ratings

11 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Oren Livnat	61%upside $27	Buy Maintained	9 May 2024
Craig-Hallum Chase Knickerbocker	38%upside $23	Buy Maintained	9 May 2024
Needham Ami Fadia	32%upside $22	Buy Reiterated	9 May 2024
Needham Ami Fadia	32%upside $22	Buy Reiterated	8 May 2024
Needham Ami Fadia	32%upside $22	Buy Reiterated	9 Apr 2024

See Analyst Rankings

Financial journalist opinion

Avadel Pharmaceuticals to Join Russell 3000® Index

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Avadel Pharmaceuticals to Join Russell 3000® Index

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA.

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy --

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Zacks Investment Research

Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges.

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET.

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

See News Rankings